Fine‐tuning of frontline tyrosine kinase inhibitor (TKI) therapy in chronic‐phase chronic myeloid leukemia: The choice of the right TKI for the right patient

In an era when tyrosine kinase inhibitors are gaining acceptance in the treatment scene of chronic‐phase chronic myeloid leukemia, this editorial focuses on the search for the optimal patient‐based frontline treatment option while evaluating a recent study by Tiribelli and colleagues, which is published in this issue of Cancer.